scholarly journals COVID-19 Tedavisinde Favipiravir Kullanımı

2021 ◽  
Vol 26 (1) ◽  
pp. 1-11
Author(s):  
Emre Kara ◽  
Ahmet Çağkan İnkaya ◽  
Kutay Demirkan ◽  
Serhat Ünal
Keyword(s):  
Adverse Effects ◽  
Drug Interactions ◽  
Literature Search ◽  
Case Reports ◽  
Treatment Options ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
The World

There are treatment options with partially shown efficacy against SARS-CoV-2. A drug with proven effect on survival has not yet been developed for the new coronavirus disease (COVID-19) defined in December 2019. Many chemicals that are being used or developed for different indications have been used for COVID-19 treatment, based on their effects observed in in vitro studies. Favipiravir, one of these drugs, was first used in Wuhan, the starting center of the pandemic. Since the spread of the infection to the world, it has been used in our country as well as countries such as Italy, Japan, Russia, Ukraine, Uzbekistan, Moldova and Kazakhstan, Bangladesh, Egypt, India. There are few studies conducted and published to evaluate the effectiveness of favipiravir, but many studies are ongoing. In this review, it was aimed to review and evaluate the studies and case reports reporting the efficacy of favipiravir in the treatment of COVID-19. With the literature search, 223 results were reached, 210 articles were fully accessed, and a total of 34 articles were included in the analysis. In the scope of the review, under the title of pharmacology of favipiravir, adverse effects and drug interactions in addition to pharmacokinetic and pharmacodynamic properties are mentioned. Favipiravir is one of the options for the treatment of COVID-19 patients, but randomized, controlled trials involving much more patients and longer follow-up periods need to be planned and the results of ongoing trials evaluated.

Oral Terbinafine: A New Antifungal Agent

1997 ◽  
Vol 31 (4) ◽  
pp. 445-456 ◽  
Author(s):  
Susan M Abdel-Rahman ◽  
Milap C Nahata
Keyword(s):  
Adverse Effects ◽  
Drug Interactions ◽  
Fungal Infections ◽  
Case Reports ◽  
Current Standard ◽  
Open Label ◽  
Double Blind ◽  
Pathogenic Yeast

Objective To review the pharmacology, pharmacokinetics, efficacy, adverse effects, drug interactions, and dosage guidelines of terbinafine. Available comparative data of terbinafine and other antimycotic agents are described for understanding the potential role of terbinafine in patient care. Data Sources A MEDLINE search restricted to English language during 1966–1996 and extensive review of journals was conducted to prepare this article. MeSH headings included allylamines, terbinafine, SF 86–327, dermatophytosis, dermatomycosis. Data Extraction The data on pharmacokinetics, adverse effects, and drug interactions were obtained from open-label and controlled studies and case reports. Controlled single- or double-blind studies were evaluated to describe the efficacy of terbinafine in the treatment of various fungal infections. Data Synthesis Terbinafine is the first oral antimycotic in the allylamines class: a fungicidal agent that inhibits ergosterol synthesis at the stage of squalene epoxidation. Terbinafine demonstrates excellent in vitro activity against the majority of dermatophyte species including Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum; less activity is seen against Dematiaceae and the filamentous fungi. It is least active against the pathogenic yeast and this correlates with the relatively poor efficacy against these organisms in vivo. High concentrations of terbinafine are achieved in keratinous tissues, the site of superficial infections, and these concentrations are maintained for up to 3 months. The clinical efficacy of terbinafine against a number of dermatophyte infections exceeds that of the current standard of therapy, griseofulvin. The efficacy of terbinafine may be as good or better than that of the azole antifungals. Additional studies are required to confirm these observations. Terbinafine demonstrates a good safety profile, and relatively few drug interactions have been identified. Conclusions Terbinafine is more effective than the gold standard, griseofulvin, in the treatment of tinea pedis and tinea unguinum, with considerably shorter treatment duration in the latter. It has been proven as effective as griseofulvin in the treatment of tinea capitis, tinea corporis, and tinea cruris. Terbinafine does not appear to offer any advantage in the treatment of nondermatophyte infections; its utility in the treatment of systemic infections has yet to be established. Depending on individual institutional costs, terbinafine may be a front-line drug for some superficial infections responding poorly to the current standard of therapy.

scholarly journals Multiple Doses of Icatibant used during Pregnancy

2017 ◽  
Vol 8 (3) ◽  
pp. ar.2017.8.0210 ◽  
Author(s):  
Lauren W. Kaminsky ◽  
Theodore Kelbel ◽  
Fay Ansary ◽  
Timothy Craig
Keyword(s):  
Adverse Events ◽  
Literature Search ◽  
Medical Literature ◽  
Case Reports ◽  
Treatment Options ◽  
Multiple Treatment ◽  
Multiple Doses ◽  
Healthy Infants

Background Hereditary angioedema (HAE) is a life-long disease that often manifests by puberty. Treatment of attacks is essential to improve quality of life and to decrease morbidity and mortality. During pregnancy, treatment is limited because multiple treatment options, including icatibant, are not approved for use during pregnancy. Objective We report the outcomes of three pregnancies during which icatibant was used by a patient with HAE with normal C1-inhibitor for treatment of attacks. We also reviewed the literature for reports of icatibant use during pregnancy for outcomes and adverse events. Methods We report on a patient who treated herself with icatibant during three separate pregnancies. Postpartum follow-up verified the health of the mother and children. We also performed a complete literature search of medical literature data bases on icatibant use during pregnancy. Results The patient in our report administered multiple doses of icatibant during three pregnancies. The child born from the first pregnancy and the child from the third pregnancy were born at term and without congenital anomalies. The child from the second pregnancy was 1-month preterm. All three children were developmentally normal. The literature search identified two case reports and one abstract of limited icatibant use without adverse events during pregnancy in patients with HAE. These pregnancies resulted in the births of healthy infants. Conclusion From a search of the literature, three cases of icatibant use during pregnancy resulted in healthy infants. In addition, we report that from icatibant use in three separate pregnancies, one infant was born prematurely, but there were no birth defects. From follow-up, the children continued meeting developmental milestones. This report adds to the acquisition of knowledge for drug adverse events during postmarketing surveillance for icatibant use during pregnancy.

scholarly journals Treatment of Tinnitus in Children—A Systematic Review

2021 ◽  
Vol 12 ◽  
Author(s):  
Max J. Dullaart ◽  
Marijn Kip ◽  
Adriana L. Smit ◽  
Inge Stegeman
Keyword(s):  
Systematic Review ◽  
Randomized Controlled Trials ◽  
Observational Studies ◽  
Case Reports ◽  
Case Series ◽  
Controlled Trials ◽  
Eligibility Criteria ◽  
Subjective Tinnitus ◽  
Randomized Controlled

Objectives: To systematically review studies on the effect of treatment of subjective tinnitus in children.Data Sources: We searched for studies in MEDLINE and EMBASE databases, after which additional studies were hand searched using Scopus databases. The methods are described in the study protocol, which has been registered in the PROSPERO register. PRISMA guidelines were followed in the reporting of this study.Eligibility Criteria: We considered for inclusion randomized controlled trials (RCTs), observational studies, case reports, and case series, with tinnitus as primary outcome in children (0–18 years old) with acute or chronic subjective tinnitus. We excluded studies in which both children and adults participated but outcomes were not specifically reported for children, as well as animal studies, studies with a non-original study design and studies about children with pulsatile or objective tinnitus.Data Selection: Two reviewers independently assessed studies for eligibility and quality, collected and extracted data. Statistical analyses were performed in case of homogeneous outcomes.Results: The search yielded a total of 4,447 studies. Of these, 147 eligible studies were selected. One case report and five observational studies met the eligibility criteria. Three studies applied counseling and (simplified-)TRT and reported improvement in tinnitus outcome in 68 out of 82 children after 3–6 months of treatment. Two studies used pharmacological treatments and reported improvement in 74 out of 86 patients after 10 days to 3 months of treatment. One study reported the outcome of biofeedback therapy, describing an improvement in tinnitus loudness and annoyance after 2 months of treatment.Conclusion: Due to the high risk of bias of the included studies, we cannot determine the effectiveness of the treatment of subjective tinnitus in children. Also, owing to brief follow-up periods, it is not possible to draw conclusions regarding long-term effects. Randomized controlled trials with longer follow-up periods are necessary to provide substantial evidence of the effects of therapies for children affected by tinnitus. https://www.crd.york.ac.uk/prospero/Systematic Review Registration:https://www.crd.york.ac.uk/prospero/, identifier [CRD42020178134].

scholarly journals Pharmacologic Treatment Options for Insomnia in Patients with Schizophrenia

Medicines ◽  
2018 ◽  
Vol 5 (3) ◽  
pp. 88 ◽  
Author(s):  
Lauren Stummer ◽  
Marija Markovic ◽  
Megan Maroney
Keyword(s):  
Sleep Disturbances ◽  
Literature Search ◽  
Treatment Options ◽  
Sodium Oxybate ◽  
Controlled Trials ◽  
Evidence Based ◽  
Pharmacologic Treatment ◽  
Search Results ◽  
Randomized Controlled ◽  
Second Generation Antipsychotic

Background: Symptoms of sleep disorders, such as disturbances in sleep initiation and continuity, are commonly reported in patients with schizophrenia, especially in the acute phase of illness. Studies have shown that up to 80% of patients diagnosed with schizophrenia report symptoms of insomnia. Sleep disturbances have been shown to increase the risk of cognitive dysfunction and relapse in patients with schizophrenia. Currently, there are no medications approved specifically for the treatment of insomnia in patients with schizophrenia. Methods: A literature search was performed through OVID and PubMed to compile publications of pharmacotherapy options studied to treat insomnia in patients with schizophrenia. Articles were reviewed from 1 January 2000 through 1 March 2018 with some additional earlier articles selected if deemed by the authors to be particularly relevant. Results: Pharmacotherapies collected from the search results that were reviewed and evaluated included melatonin, eszopiclone, sodium oxybate, and antipsychotics. Conclusions: Overall, this review confirmed that there are a few evidence-based options to treat insomnia in patients with schizophrenia, including selecting a more sedating second-generation antipsychotic such as paliperidone, or adding melatonin or eszopiclone. Further randomized controlled trials are needed.

scholarly journals Overview of Pharmacological Treatment Options for Pediatric Patients with Refractory Kawasaki Disease

2015 ◽  
Vol 20 (3) ◽  
pp. 163-177
Author(s):  
Seyyedeh Saneeymehri ◽  
Katherine Baker ◽  
Tsz-Yin So
Keyword(s):  
Kawasaki Disease ◽  
Randomized Controlled Trials ◽  
Case Reports ◽  
Treatment Options ◽  
Infectious Agent ◽  
Initial Therapy ◽  
Cytotoxic Agents ◽  
Controlled Trials ◽  
Clinical Expertise ◽  
Randomized Controlled

Kawasaki disease is an autoimmune disease found predominantly in children under the age of 5 years. Its incidence is higher in those who live in Asian countries or are of Asian descent. Kawasaki disease is characterized as an acute inflammation of the vasculature bed affecting mainly the skin, eyes, lymph nodes, and mucosal layers. Although the disease is usually self-limiting, patients may develop cardiac abnormalities that can lead to death. The exact cause of the disease is unknown; however, researchers hypothesize that an infectious agent is responsible for causing Kawasaki disease. Initial treatment options with intravenous immune globulin and aspirin are sufficient to cure most patients who acquire this disease. Unfortunately, in up to one-quarter of patients, the disease will be refractory to initial therapy and will require further management with corticosteroid, immunomodulatory, or cytotoxic agents. The lack of randomized, controlled trials makes treatment of refractory disease difficult to manage. Until larger randomized, controlled trials are published to give more guidance on therapy for this stage of disease, clinicians should use the data available from observational studies and case reports in conjunction with their clinical expertise to make treatment decisions.

scholarly journals AVALIAÇÃO DO USO DO CHÁ VERDE (CAMELLIA SINENSIS) COMO COADJUVANTE NO TRATAMENTO E CONTROLE DA DOENÇA PERIODONTAL: REVISÃO INTEGRATIVA

2021 ◽  
Vol 10 (12) ◽  
pp. 1-21
Author(s):  
Otávio Augusto Pacheco VITÓRIA ◽  
Juliano Milanezi de ALMEIDA ◽  
Vivian Cristina Noronha NOVAES
Keyword(s):  
Periodontal Disease ◽  
Green Tea ◽  
Camellia Sinensis ◽  
Case Reports ◽  
Cochrane Library ◽  
Controlled Trials ◽  
Scaling And Root Planing ◽  
Randomized Controlled ◽  
And Control

Terapias coadjuvantes ao tratamento convencional da periodontite têm sido sugeridas para otimizar os resultados terapêuticos, sendo que o chá verde tem sido proposto por apresentar propriedades benéficas ao tratamento periodontal. Nesse contexto, o objetivo desta revisão integrativa foi avaliar se o uso do chá verde é eficaz no tratamento e controle da periodontite. Para isso, foi realizado um levantamento bibliográfico nas bases de dados PubMed, Lilacs e Cochrane Library, com os descritores green tea, periodontal disease, Camellia sinensis e periodontitis. Foram selecionados artigos na língua inglesa publicados nos últimos 10 anos em que o chá verde deveria ser obrigatoriamente empregado como uma conduta terapêutica e incluídos estudos clínicos randomizados controlados e revisões sistemáticas. Foram excluídos ensaios pré-clínicos, relato de caso clínico, série de relatos clínicos, estudos epidemiológicos, editoriais, opiniões de especialistas, estudo piloto, revisões de literatura, pesquisas com resultados inconcludentes e estudos in-vitro. A busca resultou em 450 artigos dos quais, após aplicação dos critérios de inclusão e exclusão, selecionaram-se 10 artigos, sendo 8 ensaios randomizados controlados e 2 revisões sistemáticas com meta-análise. 6 artigos avaliaram a efetividade do chá verde como colutório oral demonstrando redução da inflamação e do acúmulo de placa bacteriana, 3 estudos associaram o chá verde a raspagem e alisamento radicular, demonstrando diminuição da profundidade, sangramento a sondagem e redução do quadro inflamatório e 1 estudo avaliou a ingestão sistêmica, demonstrando redução na profundidade de sondagem e sangramento. Dessa forma, podemos concluir que o chá verde é eficaz como terapia coadjuvante no tratamento e controle da periodontite. Quando associado à raspagem e ao alisamento radicular e como colutório oral, apresentam-se resultados mais satisfatórios que na forma de ingestão oral.   ASSESSMENT OF GREEN TEA (CAMELLIA SINENSIS) USED AS AN ADJUNCT TO TREATMENT AND CONTROL OF PERIODONTAL DISEASE: INTEGRATIVE REVIEW   Adjunct therapies to conventional treatment for periodontitis have been suggested to optimize therapeutic results; green tea has been suggested because it presents beneficial properties for periodontal treatment. In this context, this integrative review aims at assessing the effectiveness of green tea for periodontitis treatment and control. Thus, bibliographic research was carried out in PubMed, LILACS, and Cochrane Library databases, using the words green tea, periodontal disease, Camelliasinensis, and periodontitis as keywords. Articles in English language issued in the last 10 years were screened, in which green tea was imperatively used as a therapeutic approach and included randomized controlled trials and systematic reviews. Pre-clinical trials, clinical case reports, series of case reports, epidemiological studies, editorials, expert opinions, pilot study, literature review, researches with inconclusive results, and in-vitro studies were excluded. The search resulted in 450 articles in which, after applying inclusion and exclusion criteria, 10 articles were screened, being 10 articles, 8 randomized controlled trials, and 2 systemic reviews and meta-analysis. 6 articles assessed the effectiveness of green tea as mouthwash and presenting a reduction either in inflammation and the accumulation of bacterial plaque, 3 studies associated green tea to scaling and root planing, indicating a decrease in the depth, bleeding when drilling, and reduction in the inflammatory process, 1 study assessed the systemic intake, indicating a reduction in drilling depth and bleeding. Thus, we can conclude that green tea is efficient as adjuvant therapy to the treatment and control of periodontitis. When associated with scaling and root planing, and used as a mouthwash, the results were more satisfactory when it was used as a mouthwash than when it was ingested.   Keywords: Tea. Camelliasinensis. Periodontal Diseases. Periodontology.

scholarly journals Efficacy and safety of erythropoietin for traumatic brain injury: a meta-analysis of randomized controlled trials

2019 ◽  
Author(s):  
Motao Liu ◽  
Amy J. Wang ◽  
Gexin Zhao ◽  
Hua He ◽  
Ziv M. Williams ◽  
...  
Keyword(s):  
Traumatic Brain Injury ◽  
Brain Injury ◽  
Adverse Effects ◽  
Adverse Events ◽  
Hospital Mortality ◽  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Randomized Controlled

AbstractObjectiveRecent studies regarding the effects of erythropoietin (EPO) for treating traumatic brain injury (TBI) have been inconsistent. This study conducts a meta-analysis of randomized controlled trials (RCTs) to assess the safety and efficacy of EPO for TBI patients at various follow-up time points.MethodsA literature search was performed using PubMed, Web of Science, MEDLINE, Embase, Google Scholar and the Cochrane Library for RCTs studying EPO in TBI patients published through March 2019. Non-English manuscripts and non-human studies were excluded. The assessed outcomes include mortality, neurological recovery and associated adverse effects. Dichotomous variables are presented as risk ratios (RR) with a 95% confidence interval (CI).ResultsA total of seven RCTs involving 1197 TBI patients were included in this study. Compared to the placebo arm, treatment with EPO did not improve acute hospital mortality or short-term mortality. However, there was a significant improvement in mid-term (6 months) follow-up survival rates. EPO administration was not associated with neurological function improvement. Regarding adverse effects, EPO treatment did not increase the incidence of thromboembolic events or other associated adverse events.ConclusionsThis meta-analysis indicates a slight mortality benefit for TBI patients treated with EPO at mid-term follow-up. EPO does not improve in-hospital mortality, nor does it increase adverse events including thrombotic, cardiovascular and other associated complications. Our analysis did not demonstrate a significant beneficial effect of EPO intervention on the recovery of neurological function. Future RCTs are required to further characterize the use of EPO in TBI.

scholarly journals Efficacy and safety of erythropoietin for traumatic brain injury: a meta-analysis of randomized controlled trials

2020 ◽  
Author(s):  
Motao Liu ◽  
Amy J. Wang ◽  
Yu Chen ◽  
Gexin Zhao ◽  
Zhifeng Jiang ◽  
...  
Keyword(s):  
Traumatic Brain Injury ◽  
Brain Injury ◽  
Adverse Effects ◽  
Adverse Events ◽  
Hospital Mortality ◽  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Randomized Controlled

Abstract Background Recent studies regarding the effects of erythropoietin (EPO) for treating traumatic brain injury (TBI) have been inconsistent. This study conducts a meta-analysis of randomized controlled trials (RCTs) to assess the safety and efficacy of EPO for TBI patients at various follow-up time points. Methods A literature search was performed using PubMed, Web of Science, MEDLINE, Embase, Google Scholar and the Cochrane Library for RCTs studying EPO in TBI patients published through March 2019. Non-English manuscripts and non-human studies were excluded. The assessed outcomes include mortality, neurological recovery and associated adverse effects. Dichotomous variables are presented as risk ratios (RR) with a 95% confidence interval (CI). Results A total of seven RCTs involving 1197 TBI patients were included in this study. Compared to the placebo arm, treatment with EPO did not improve acute hospital mortality or short-term mortality. However, there was a significant improvement in mid-term (6 months) follow-up survival rates. EPO administration was not associated with neurological function improvement. Regarding adverse effects, EPO treatment did not increase the incidence of thromboembolic events or other associated adverse events.Conclusions This meta-analysis indicates a slight mortality benefit for TBI patients treated with EPO at mid-term follow-up. EPO does not improve in-hospital mortality, nor does it increase adverse events including thrombotic, cardiovascular and other associated complications. Our analysis did not demonstrate a significant beneficial effect of EPO intervention on the recovery of neurological function. Future RCTs are required to further characterize the use of EPO in TBI.

Antidepressant-Induced Sexual Dysfunction

2002 ◽  
Vol 36 (10) ◽  
pp. 1577-1589 ◽  
Author(s):  
Razmic S Gregorian ◽  
Katharine A Golden ◽  
Asena Bahce ◽  
Clifford Goodman ◽  
W Jacqueline Kwong ◽  
...  
Keyword(s):  
Adverse Effect ◽  
Sexual Dysfunction ◽  
Adverse Effects ◽  
Randomized Controlled Trials ◽  
Antidepressant Treatment ◽  
Case Reports ◽  
Data Extraction ◽  
Common Adverse Effect ◽  
Controlled Trials ◽  
Randomized Controlled

OBJECTIVE: To review the evidence regarding antidepressant-induced sexual dysfunction and address implications for treatment strategy and health plan coverage policies for antidepressant medications. DATA SOURCES: Primary articles were identified by a MEDLINE and HealthSTAR search to identify English-language studies published between January 1986 and July 2000. Search terms included sexual dysfunction or sexual function and antidepressants, fluoxetine, sertraline, paroxetine, fluvoxamine, citalopram, venlafaxine, nefazodone, bupropion, and mirtazapine. A cross-check of references cited in 10 published reviews yielded additional in-scope articles. STUDY SELECTION AND DATA EXTRACTION: Approximately 200 articles were identified, including 8 randomized controlled trials and numerous open-label studies, case series, and case reports. Of the randomized controlled trials, only 5 were designed to evaluate the incidence of sexual dysfunction associated with antidepressant treatment. Three additional randomized controlled trials included a structured assessment of sexual dysfunction within an efficacy trial. Data extraction excluded case reports, letters, and other limited study designs. A panel survey augmented published reports. DATA SYNTHESIS: Sexual dysfunction is a relatively common adverse effect of many of the antidepressants in common use today. Rates of sexual dysfunction observed in clinical practice may be higher than those reported in the product information for several agents. Selective serotonin-reuptake inhibitors (SSRIs) appear to be the class of antidepressants most likely to cause sexual dysfunction. Published studies suggest that between 30% and 60% of SSRI-treated patients may experience some form of treatment-induced sexual dysfunction. Bupropion and nefazodone appear to be much less likely to cause sexual dysfunction (≤10% of patients). Mirtazapine also appears to be associated with a low rate of sexual adverse effects. Panel results largely reflect the consensus of the literature. CONCLUSIONS: Sexual dysfunction is a common adverse effect of antidepressant treatment. Physicians should monitor their patients for antidepressant-induced sexual adverse effects, as these may affect compliance with therapy and ultimate treatment success. In addition to the consequences for patient health and well-being, managed-care organizations should be concerned with sexually related adverse effects of antidepressants, insofar as additional healthcare resources may be required to treat depressed patients in whom these adverse effects arise.

scholarly journals Comparison of Arthroscopic Partial Meniscectomy to Physical Therapy following Degenerative Meniscus Tears: A Systematic Review and Meta-analysis

2020 ◽  
Vol 2020 ◽  
pp. 1-9
Author(s):  
Juntan Li ◽  
Wannan Zhu ◽  
Xiang Gao ◽  
Xu Li
Keyword(s):  
Physical Therapy ◽  
Functional Outcomes ◽  
Literature Search ◽  
Controlled Trials ◽  
Arthroscopic Partial Meniscectomy ◽  
Randomized Controlled ◽  
Meniscus Tears ◽  
Small Benefit ◽  
Time Point

Objective. To compare the effectiveness of arthroscopic partial meniscectomy (APM) and physical therapy (PT) for degenerative meniscus tears. Method. We conducted a literature search through PubMed, Embase, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov. Randomized controlled trials in adults with degenerative meniscal tears without symptoms of locking were considered for inclusion. Two researchers independently performed the literature search, assessed the risk of bias, and selected eligible studies. The primary outcome was function at different follow-up time points and the secondary outcome was pain at different follow-up time points. Results. We included 6 randomized controlled trials, with a total of 1006 participants, among which 495 were in the APM group and 511 were in the PT group. We found a small benefit in functional outcomes in the APM group until the 12 months follow-up time point (SMD=0.20; 95%CI=0.0‐0.33; p=0.002; I2=34%), but no significant differences in function between groups at the 24-month follow-up time point (SMD=0.12; 95%CI=−0.04−0.28;p=0.14; I2=28%). There was also small benefit in the APM group until the 12 months follow-up time point for pain (SMD=0.14; 95%CI=0.01−027; p=0.03; I2=36%), but no significant difference in pain between groups at 24 months (SMD=0.11; 95%CI=−0.05−0.28; p=0.18; I2=0%). Conclusion. In the treatment of degenerative meniscus tears, APM yielded better functional and pain outcomes compared with physical therapy in the short term until 12 months, but there were comparable results for pain and functional outcomes between the groups at the 24 months follow-up time point.

Sign in / Sign up

Export Citation Format

Share Document